神经障碍性流涎的新型肉毒毒素 A：真实世界经验。
Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience.
机构信息
Department of Neurology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
Department of Neurodegenerative Diseases, UCL Institute of Neurology, London WC1N 3RX, UK.
出版信息
Toxins (Basel). 2018 May 28;10(6):217. doi: 10.3390/toxins10060217.
Botulinum toxin type A is one of the most useful treatments of sialorrhea in neurological disorders. Evidence for the use of incobotulinumtoxin A (inco-A) in the treatment of sialorrhea is limited. Thirty-six patients with sialorrhea were treated with infiltrations of inco-A into both parotid glands. The severity of sialorrhea was evaluated by the Drooling Severity Scale (DSS), and the Drooling Frequency Scale (DFS). Patients' perceptions of clinical benefit were recorded via the Patient Global Impression of Improvement (PGI-I) scale. Following treatment, there was a significant difference in both the DFS and the DSS ( < 0.001). Clinical benefits on the basis of the PGI-I were present in up to 90% of patients.
A型肉毒毒素是治疗神经障碍性流涎症最有效的方法之一。使用注射用型肉毒毒素（inco-A）治疗流涎症的证据有限。36 例流涎症患者接受了 inco-A 双侧腮腺内注射治疗。流涎严重程度采用流涎严重程度量表（Drooling Severity Scale，DSS）和流涎频率量表（Drooling Frequency Scale，DFS）进行评估。通过患者总体改善印象量表（Patient Global Impression of Improvement，PGI-I）记录患者对临床获益的感知。治疗后，DFS 和 DSS 均有显著差异（<0.001）。根据 PGI-I，多达 90%的患者存在临床获益。
Zotero 插件